Montreal, Canada – February 3, 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today that François Ravenelle, PhD, CEO, will participate to the private company days of the 11th Annual SVB Leerink Global Healthcare Conference.
Conference held virtually, Feb.14-18, 2022
Private Company Days: Monday, Feb. 14 and Tuesday, Feb. 15.
SVB Leerink is a leading investment bank, specializing in healthcare and technology. The firm’s knowledge, experience and focus enable it to help its clients define and achieve their strategic, capital markets and investment objectives.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.